Clearstead Trust’s 10x Genomics TXG Stock Holding History

Clearstead Trust’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.76K	Hold	46	–	–	﹤0.01%	896
2026 Q1	$977	Hold	46	–	–	﹤0.01%	937
2025 Q4	$751	Buy	+46	New	+$695	﹤0.01%	962

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clearstead Trust's TXG Position: Q2 2026 in Review

Clearstead Trust held its 10x Genomics (TXG) position steady in Q2 2026 at 46 shares worth $1.76K. The position accounts for ﹤0.01% of the portfolio, ranked #896.

Clearstead Trust first reported a position in TXG in Q4 2025 and has held it in 3 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Clearstead Trust held 46 shares of 10x Genomics worth $1.76K as of Q2 2026.
Clearstead Trust left its 10x Genomics share count unchanged in Q2 2026.
10x Genomics made up ﹤0.01% of Clearstead Trust's portfolio in Q2 2026, its #896 holding.
Clearstead Trust first reported a position in 10x Genomics in Q4 2025 and has held it in 3 quarters since.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Clearstead Trust's 13F filing for Q2 2026, filed 6 Aug 2026.